Latest News
Cellectar Biosciences, Inc.
- Cellectar reports trial data for cancer drug in rare disease
- Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
- Cancer treatment responses lasted a median 16 months in Cellectar's study
- Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
- Cellectar plans Phase 3 trial, regulatory filing for WM treatment By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →